Effect of pentoxifillyn on COVID-19

Investigating the effect of Pentoxifylline drug on the clinical progression of covid-19 in patients with acute respiratory failure of moderate severity in the intervention and control groups

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210517051326N1

Enrollment

Registered

2023-04-27

Start date

2022-05-22

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Acute respiratory failure with hypoxia

Interventions

Intervention 1: Intervention group: A Participants with usual treatment (curcudone 35 mg daily, vitamin C loan 500 mg daily, heparin 5000 units every 12 hours, dexamethasone 4 mg IV daily), pentoxifyl

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Positive test of PCR test COVID-19 ??Age more than 18 SpO2 more than 90%

Exclusion criteria

Exclusion criteria: Sever COVID-19 Need for treatment with Mechanical ventilation Need for treatment with high dose corticosteroids Nausea and vomiting and GIB

Design outcomes

Primary

Measure	Time frame
Spo2. Timepoint: 1st, 7th, 28th, 35th day. Method of measurement: Pulseoximetry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSedeqe Sadat Akhlaghi

Shahid Beheshti University of Medical Sciences

sediqakhlaghi@yahoo.com+98 21 2303 1335

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026